Hyloris Funding Round Raises €15m

Value Added Medicines Specialist Eyes 505(b)(2) Route In US

 
• By Dave Wallace

Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.

Coins_Funding
Hyloris has just completed a funding round • Source: Shutterstock

More from Strategy

More from Business